Company / Free Cash Flow
Ligand Pharmaceuticals, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$48.9M
FY2025
5-year range
$46.1M / $119.9M
FY2021-FY2025
Trend
-48.6%
vs FY2024
Sector context
#52 of 194
Health Care
What the data says
At $49M, Ligand Pharmaceuticals, Inc.'s free cash flow ranks #52 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 10 years, ranging from -$32M in FY2019 to $193M in FY2018.
Based on SEC 10-K filings.
$49M in FY2025 with a 5-year CAGR of -0.5%.
Improved from $46M to $49M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -25.8%
- 5-Year CAGR
- -0.5%
- 10-Year CAGR
- -
Sector benchmark
#52 of 194 in Health CareTop 27% of 194This company $48.9M Sector average $470.6M
▼
-89.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.5%, indicating a declining trend.
- In FY2025, free cash flow decreased 48.6% year-over-year.
- Ranks #52 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.9M | -48.6% |
| FY2024 | $95.2M | +106.8% |
| FY2023 | $46.1M | -61.6% |
| FY2022 | $119.9M | +71.2% |
| FY2021 | $70.0M | +39.7% |
| FY2020 | $50.1M | +257.2% |
| FY2019 | -$31.9M | -116.5% |
| FY2018 | $193.2M | +123.5% |
| FY2017 | $86.4M | +46.8% |
| FY2016 | $58.9M | +41.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026